Molecular heterogeneity of inflammatory breast cancer: A hyperproliferative phenotype

Clinical Cancer Research

Volumn 12, Issue 17, 2006, Pages 5047-5054

  Nguyen, Dang M ^a   Sam, Kathy ^a   Tsimelzon, Anna ^a   Li, Xiaoxian ^a   Wong, Helen ^a   Mohsin, Syed ^a   Clark, Gary M ^a   Hilsenbeck, Susan G ^a   Elledge, Richard M ^a   Allred, D Craig ^a   O'Connell, Peter ^a   Chang, Jenny C ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; STEROID RECEPTOR; UVOMORULIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; ERYTHEMA; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLIC RATE; PHENOTYPE; PRIORITY JOURNAL; TISSUE MICROARRAY;

BREAST NEOPLASMS; CELL PROLIFERATION; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEDIGREE; PHENOTYPE;

EID: 33749012842     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2248     Document Type: Article

References (30)

1. Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of memorial hospital. Surg Gynecol Obstet 1924;39:580-5.
2. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J Natl Cancer Inst 1985;74:291-7.
3. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-24.
4. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966-75.
5. Paradiso A, Tommasi S, Brandi M, et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989;64:1922-7.
6. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000;2:418-25.
7. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98:31-6.
8. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003;19:2448-55.
9. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-84.
10. Pavlidis P, Qin J, Arango V, Mann JJ, Sibille E. Using the Gene Ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res 2004;29:1213-22.
11. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
12. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki67. Am J Pathol 1991;138:867-73.
13. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
14. Wintzer H, Zipfel I, Schulte-Mounting J, Hellerich U, von Kleist S. Ki67 immunostaining in human breast tumours and its relationship to prognosis. Cancer 1991;67:421-8.
15. Krajewski S, Mai JK, Krajewska M, Sikorska M, Mossakowski MJ, Reed JC. Upregulation of bax protein levels in neurons following cerebral ischemia. J Neurosci 1995;15:6364-76.
16. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC bcl-2 and apoptosis in lymph node positive breast carcinoma Cancer 1998;82:1296-302
17. Polyak K. Is p53 a breast cancer gene? Cancer Biol Ther 2002;1:37-8
18. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer, mutation and nuclear exclusion. Proc Natl Acad Sci U S A 1992;89:7262-6.
19. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-9
20. Charafe-Jauffret E, Tarpin C, Bardou VJ, et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an "inflammatory signature." J Pathol 2004;202:265-73.
21. Parker C, Rampaul RS, Pinder SE, et al. E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 2001;85:1958-63.
22. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005;65:2170-8.
23. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy Cancer Res 2004;64:8558-65.
24. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004;10:6789-95.
25. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.
26. Pertschuk LP, Kim DS, Nayer K, et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990;66:1663-70.
27. Crowe JP, Hubay CA, Pearson OH, et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 1982;2:171-6.
28. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
29. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
30. Van Laere S, Van der Auwera I, Van den Eynden GG, et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 2005;93:237-46.